| Advanced Technologies and Regenerative Medicine, LLC Patent applications |
| Patent application number | Title | Published |
|---|
| 20120027775 | ABSORBABLE PEG-BASED HYDROGELS - An absorbable PEG-based hydrogel prepared from a multi-arm-PEG-vinylsulfone having about 3 to about 8 arms and a multi-arm-PEG-R-sulfhydryl having about 3 to about 8 arms; where R is defined as an ester linkage, such as carboxylate ester, lactate ester, and isobutyrate ester have been disclosed. Additionally, sustained release compositions that are prepared from an absorbable PEG-based hydrogel and a protein have been disclosed which provide sustained release of proteins and peptides. | 02-02-2012 |
| 20120014921 | TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS VIA INTRANASAL ADMINISTRATION OF UMBILICAL CORD-DERIVED CELLS - This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients. | 01-19-2012 |
| 20110280838 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells and optionally a hydrogel. In some embodiments, administering the cells promotes repair and regeneration of degenerated IVD tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided. | 11-17-2011 |
| 20110237506 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 09-29-2011 |
| 20110230406 | AFFINITY PEPTIDES TOWARD BMP-2 - We have disclosed affinity peptides toward BMP-2. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for BMP-2. | 09-22-2011 |
| 20110223205 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING UMBILICAL DERIVED CELLS - This invention relates to methods of treating amyotrophic lateral sclerosis. In particular, the invention provides for methods of treating amyotrophic lateral sclerosis by administering umbilical cord tissue-derived cells, an effective amount of a substantially homogenous population of umbilical cord tissue-derived cells or a pharmaceutical composition comprising umbilical cord tissue-derived cells to a patient. | 09-15-2011 |
| 20110142805 | METHOD OF RENAL REPAIR AND REGENERATION AND THE TREATMENT OF DIABETIC NEPHROPATHY - We have disclosed methods for treating chronic kidney disease. More specifically, we have disclosed methods for treating diabetic nephropathy with human kidney derived cells. | 06-16-2011 |
| 20110076769 | MAMMARY ARTERY DERIVED CELLS AND METHODS OF USE IN TISSUE REPAIR AND REGENERATION - An isolated mammalian internal mammary artery-derived cell is disclosed. Furthermore, methods of isolating the mammalian internal mammary artery-derived cell are disclosed. The cell is useful in tissue engineering technologies, specifically in vascular tissue engineering. | 03-31-2011 |
| 20100130730 | PROTEIN FORMULATIONS FOR USE AT ELEVATED TEMPERATURES - Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature. | 05-27-2010 |
| 20090259023 | LIQUID BUFFERED GDF-5 FORMULATIONS - Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of the GDF-5 protein during storage, handling, and use. | 10-15-2009 |
| 20090246247 | COMPOSITE ENTEROCYSTOPLASTY - The present invention relates to methods for tissue augmentation or regeneration. More specifically, the present invention provides for a composite enterocystoplasty procedure using a biocompatible scaffold and minced autologous tissue for implantation in a mammalian bladder. | 10-01-2009 |
